The FDA has approved extending Eylea HD dosing intervals to 20 weeks for patients with wAMD and DME who responded well after a year, based on PULSAR and PHOTON trial data. This allows personalized treatment options for anti-VEGF therapy.

NodeGuardian

2026-04-14 20:04:55

Abstract generation in progress

The FDA has approved extending the dosing intervals for Regeneron’s Eylea HD up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) who have shown a successful response after one year. This update, based on 96-week data from the PULSAR and PHOTON trials, allows for individualized treatment plans, offering the broadest dosing range for an injectable anti-VEGF treatment. Regeneron is also awaiting FDA review for an Eylea HD prefilled syringe.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

3 Likes

Reward
3
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
WCTCTradingChallengeShare8MUSDT
668.74K Popularity
#
GateMarchTransparencyReport
29.82K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
765.69K Popularity
#
USBlocksStraitofHormuz
737.75K Popularity
#
Gate13thAnniversary
178.72K Popularity

Sitemap

FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD

Trending Topics

WCTCTradingChallengeShare8MUSDT

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

Gate13thAnniversary

Pin